Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol to Prevent Decompensation in Cirrhosis (CARVECIR)
NCT06263816Phase 3Not yet recruiting
- Sponsor
- University Hospital Tours
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis and Portal Hypertension (PH) comparing Carvedilol with Placebo (2 arms). Primary endpoint: Occurrence of decompensation of cirrhosis or liver-related death at 36 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT06263816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263816.